Serum Institute of India CEO Adar Poonawalla has said that the production of Covid-19 vaccine Covishield is in full swing in Pune and he will review the operations once he is back in the country.
SII is manufacturing AstraZeneca-Oxford University’s Covishield vaccine in India.
“Had an excellent meeting with all our partners & stakeholders in the U.K.,” Poonawalla tweeted, adding that Covishield production is in full swing in Pune.
The statement came after he indicated in an interview with ‘The Times’ that he is in London currently due to business plan to start production of Covishield outside India,. The company will soon make an announcement on the issue.
“There’s going to be an announcement in the next few days,” he had said when asked about Britain as one of the production bases outside India.
In a major move, SII had reduced the price of its COVID-19 vaccine ‘Covishield’ from Rs 400 to Rs 300 per dose for states on Wednesday.
The Ministry of Home Affairs (MHA) on Wednesday also provided Poonawalla with Y category security across the country by the Central Reserve Police Force (CRPF).
The Ministry of Home Affairs (MHA) on Wednesday also provided Poonawalla with Y category security across the country by the Central Reserve Police Force (CRPF).
Earlier this month, Adar Poonawalla had asked the government for financial assistance to ramp up vaccine production.
